CHICAGO , Sept. 11, 2025 /PRNewswire/ -- EVERSANA , a leading provider of global commercialization services to the life sciences industry, has been named by Precigen, Inc. for commercialization of PAPZIMEOS™ (zopapogene imadenovec-drba), approved by the U.S. Food and Drug Administration on August 14, 2025 .

Since partnering in late 2024, Precigen has leveraged EVERSANA's full-scale commercialization operation for pre-approval planning and has activated immediate post-approval launch services, including areas covered by market access, field deployment, medical affairs, and marketing services.

"Our model is built to overcome the complexity of rare disease therapy launches," said Greg Skalicky , President, EVERSANA. "We will immediately deploy our ever-evolving capabilities t

See Full Page